Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
PR Newswire•22/09/2026•07:00 ET
0
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 PR Newswire
- The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve -
Get started
Create a free account to read the full story and Whiz Insights.